GlaxoSmithKline plc (GSK) Receives Average Recommendation of “Hold” from Brokerages

GlaxoSmithKline plc (LON:GSK) has been given an average recommendation of “Hold” by the eighteen brokerages that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is GBX 1,601.92 ($20.93).

Several equities research analysts have recently weighed in on the stock. Barclays reissued an “equal weight” rating on shares of GlaxoSmithKline in a research report on Wednesday, April 10th. Credit Suisse Group set a GBX 1,600 ($20.91) target price on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Wednesday, April 10th. Deutsche Bank reissued a “hold” rating and issued a GBX 1,520 ($19.86) target price on shares of GlaxoSmithKline in a research report on Friday, April 5th. Shore Capital downgraded shares of GlaxoSmithKline to a “hold” rating in a research report on Friday, January 18th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, March 14th.

In other GlaxoSmithKline news, insider Jesse Goodman purchased 845 shares of the firm’s stock in a transaction dated Wednesday, February 6th. The stock was acquired at an average cost of GBX 1,964 ($25.66) per share, with a total value of £16,595.80 ($21,685.35). Also, insider Emma Walmsley sold 9,053 shares of GlaxoSmithKline stock in a transaction dated Monday, February 18th. The shares were sold at an average price of GBX 1,576 ($20.59), for a total transaction of £142,675.28 ($186,430.52). Insiders bought a total of 3,873 shares of company stock valued at $6,343,952 over the last ninety days.

GSK opened at GBX 1,550 ($20.25) on Tuesday. The stock has a market capitalization of $76.59 billion and a PE ratio of 21.26. GlaxoSmithKline has a 1-year low of GBX 1,395.80 ($18.24) and a 1-year high of GBX 1,648.80 ($21.54). The company has a quick ratio of 0.47, a current ratio of 0.75 and a debt-to-equity ratio of 709.80.

The firm also recently declared a dividend, which was paid on Thursday, April 11th. Stockholders of record on Thursday, February 21st were issued a GBX 23 ($0.30) dividend. The ex-dividend date of this dividend was Thursday, February 21st. This is a positive change from GlaxoSmithKline’s previous dividend of $19.00. This represents a dividend yield of 1.49%. GlaxoSmithKline’s payout ratio is 1.26%.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Article: NASDAQ

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit